Increased sphingoid base-1-phosphates and failure of neural tube closure after exposure to fumonisin or FTY720

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 94, Issue 10, 2012, Pages 790-803

  Gelineau van Waes, Janee ^a   Rainey, Mark A ^a   Maddox, Joyce R ^a   Voss, Kenneth A ^b   Sachs, Andrew J ^a   Gardner, Nicole M ^a   Wilberding, Justin D ^c   Riley, Ronald T ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSSELL RESEARCH CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Ceramide synthase; Exencephaly; FTY720; Fumonisin; Mycotoxin; Neural progenitor cells; Neural tube defect; S1P receptors; Sphinganine 1 phosphate; Sphingolipid

Indexed keywords

BIOLOGICAL MARKER; FINGOLIMOD; FUMONISIN; LIGAND; SPHINGANINE; SPHINGANINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; EMBRYO; EMBRYONAL TISSUE; EXENCEPHALY; FEMALE; FIBROBLAST; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; MOUSE EMBRYO; MOUSE STRAIN; NEURAL STEM CELL; NEURAL TUBE DEFECT; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANIMALS; CELLS, CULTURED; EMBRYO, MAMMALIAN; FEMALE; FUMONISINS; MICE; MICE, INBRED STRAINS; MODELS, BIOLOGICAL; NEURAL TUBE DEFECTS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROPYLENE GLYCOLS; SPHINGOSINE; UP-REGULATION;

EID: 84867679589     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23074     Document Type: Article

References (84)

1. Bengtsson H, Epifantseva I, Abrink M, et al. 2008. Generation and characterization of a Gdf1 conditional null allele. Genesis 46: 368-372.
2. Bielawski J, Szulc ZM, Hannun YA, et al. 2006. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39: 82-91.
3. Boulet SL, Yang Q, Mai C, et al. 2008. Trends in the postfortification prevalence of spina bifida and anencephaly in the United States. Birth Defects Res A Clin Mol Teratol 82: 527-532.
4. Brinkmann V. 2007. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115: 84-105.
5. Brinkmann V, Davis MD, Heise CE, et al. 2002. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453-21457.
6. Callihan P, Zitomer NC, Stoeling MV, et al. 2012. Distinct generation, pharmacology, and distribution of sphingosine 1-phosphate and dihydrosphingosine 1-phosphate in human neural progenitor cells. Neuropharmacology 62: 988-996.
7. Cyster JG. 2005. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23: 127-159.
8. Dev KK, Mullershausen F, Mattes H, et al. 2008. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 117: 77-93.
9. Dragun D, Fritsche L, Boehler T, et al. 2004. FTY720: early clinical experience. Transplant Proc 36: 544S-548S.
10. Escalante-Alcalde D, Morales SL, Stewart CL, et al. 2009. Generation of a reporter-null allele of Ppap2b/Lpp3and its expression during embryogenesis. Int J Dev Biol 53: 139-147.
11. Escalante-Alcalde D, Sanchez-Sanchez R, Stewart CL, et al. 2007. Generation of a conditional Ppap2b/Lpp3 null allele. Genesis 45: 465-469.
12. Futerman AH, Hannun YA. 2004. The complex life of simple sphingolipids. EMBO Rep 5: 777-782.
13. Gelineau-van Waes J, Starr L, Maddox J, et al. 2005. Maternal fumonisin exposure and risk for neural tube defects: mechanisms in an in vivo mouse model. Birth defects research 73: 487-497.
14. Gelineau-van Waes J, Voss KA, Stevens VL, et al. 2009. Maternal fumonisin exposure as a risk factor for neural tube defects. Adv Food Nutr Res 56: 145-181.
15. Gong YY, Torres-Sanchez L, Lopez-Carrillo L, et al. 2008. Association between tortilla consumption and human urinary fumonisin B1 levels in a Mexican population. Cancer Epidemiol Biomarkers Prev 17: 688-694.
16. Hanel P, Andreani P, Graler MH, et al. 2007. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 21: 1202-1209.
17. Hendricks K. 1999. Fumonisins and neural tube defects in South Texas. Epidemiology 10: 198-200.
18. Hisano Y, Kobayashi N, Kawahara A, et al. 2011. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720 J Biol Chem 286: 1758-1766.
19. Hurst JH, Mumaw J, Machacek DW, et al. 2008. Human neural progenitors express functional lysophospholipid receptors that regulate cell growth and morphology. BMC Neurosci 9: 118.
20. Ito K, Anada Y, Tani M, et al. 2007. Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun 357: 212-217.
21. Kobayashi N, Kobayashi N, Yamaguchi A, et al. 2009. Characterization of the ATP-dependent sphingosine 1-phosphate transporter in rat erythrocytes. J Biol Chem 284: 21192-21200.
22. Kono M, Mi Y, Liu Y, et al. 2004. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis J Biol Chem 279: 29367-29373.
23. Kovarik JM, Schmouder RL, Slade AJ, et al. 2004. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit 26: 585-587.
24. Kromberg JG, Jenkins T. 1982. Common birth defects in South African Blacks. S Afr Med J 62: 599-602.
25. Kusumoto K, Parton A, Barnes D, et al. 2009. Mitogen limitation and bone morphogenetic protein-4 promote neurogenesis in SFME cells, an EGF-dependent neural stem cell line. In Vitro Cell Dev Biol Anim 45: 55-61.
26. Le Stunff H, Mikami A, Giussani P, et al. 2004a. Role of sphingosine-1-phosphate phosphatase 1 in epidermal growth factor-induced chemotaxis. J Biol Chem 279: 34290-34297.
27. Le Stunff H, Milstien S, Spiegel S, et al. 2004b. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem 92: 882-899.
28. Le Stunff H, Peterson C, Liu H, et al. 2002. Sphingosine-1-phosphate and lipid phosphohydrolases. Biochim Biophys Acta 1582: 8-17.
29. Leck I. 1983. Spina bifida and anencephaly: fewer patients, more problems. Br Med J (Clin Res Ed) 286: 1679-1680.
30. Lee SJ. 1991. Expression of growth/differentiation factor 1 in the nervous system: conservation of a bicistronic structure. Proc Natl Acad Sci U S A 88: 4250-4254.
31. Levy M, Futerman AH. 2010. Mammalian ceramide synthases. IUBMB Life 62: 347-356.
32. Marasas WF. 1996. Fumonisins: history, world-wide occurrence and impact. Adv Exp Med Biol 392: 1-17.
33. Marasas WF, Riley RT, Hendricks KA, et al. 2004. Fumonisins disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: a potential risk factor for human neural tube defects among populations consuming fumonisin-contaminated maize. J Nutr 134: 711-716.
34. Mechtcheriakova D, Wlachos A, Sobanov J, et al. 2007. FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3. FEBS Lett 581: 3063-3068.
35. Melnick M, Marazita ML. 1998. Neural tube defects, methylenetetrahydrofolate reductase mutation, and north/south dietary differences in China. J Craniofac Genet Dev Biol 18: 233-235.
36. Meng H, Lee VM. 2009. Differential expression of sphingosine-1-phosphate receptors 1-5 in the developing nervous system. Dev Dyn 238: 487-500.
37. Meredith FI, Torres OR, Saenz de Tejada S, et al. 1999. Fumonisin B1 and hydrolyzed fumonisin B1 (AP1) in tortillas and nixtamalized corn (Zea mays L.) from two different geographic locations in Guatemala. J Food Prot 62: 1218-1222.
38. Merrill AHJr, Sullards MC, Wang E, et al. 2001. Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins. Environmental health perspectives 109 Suppl 2: 283-289.
39. Miller J. 2001. Occurrence of Fusarium and fumonisins on food grains and in foods. Environ Health Perspect 109 Suppl 2: 321-324.
40. Missmer SA, Suarez L, Felkner M, et al. 2006. Exposure to fumonisins and the occurrence of neural tube defects along the Texas-Mexico border. Environ Health Perspect 114: 237-241.
41. Mizugishi K, Yamashita T, Olivera A, et al. 2005. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 25: 11113-11121.
42. Mizutani Y, Kihara A, Igarashi Y. 2005. Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J 390: 263-271.
43. Moore CA, Li S, Li Z, et al. 1997. Elevated rates of severe neural tube defects in a high-prevalence area in northern China. Am J Med Genet 73: 113-118.
44. Murata N, Sato K, Kon J, et al. 2000. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 352 Pt 3: 809-815.
45. Murray JC, Daack-Hirsch S, Buetow KH, et al. 1997. Clinical and epidemiologic studies of cleft lip and palate in the Philippines. Cleft Palate Craniofac J 34: 7-10.
46. Ncayiyana DJ. 1986. Neural tube defects among rural blacks in a Transkei district. A preliminary report and analysis. S Afr Med J 69: 618-620.
47. Norred WP, Plattner RD, Dombrink-Kurtzman MA, et al. 1997. Mycotoxin-induced elevation of free sphingoid bases in precision-cut rat liver slices: specificity of the response and structure-activity relationships. Toxicol Appl Pharmacol 147: 63-70.
48. Ohuchi H, Hamada A, Matsuda H, et al. 2008. Expression patterns of the lysophospholipid receptor genes during mouse early development. Dev Dyn 237: 3280-3294.
49. Okajima F. 2002. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochem Biophys Acta 1582: 132-137.
50. Paugh SW, Payne SG, Barbour SE, et al. 2003. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 554: 189-193.
51. Pewzner-Jung Y, Ben-Dor S, Futerman AH, et al. 2006. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis. J Biol Chem 281: 25001-25005.
52. Prakash K, Pirozzi G, Elashoff M, et al. 2002. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Nat Acad Sci U S A 99: 7598-7603.
53. Riley RT, An NH, Showker JL, et al. 1993. Alteration of tissue and serum sphinganine to sphingosine ratio: an early biomarker of exposure to fumonisin-containing feeds in pigs. Toxicol Appl Pharmacol 118: 105-112.
54. Riley RT, Voss KA. 2006. Differential sensitivity of rat kidney and liver to fumonisin toxicity: organ-specific differences in toxin accumulation and sphingoid base metabolism. Toxicol Sci 92: 335-345.
55. Riley RT, Wang E, Schroeder JJ, et al. 1996. Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins. Nat Toxins 4: 3-15.
56. Riley RT, Torres O, Showker, et al. 2012. The kinetics of urinary fumonisin B1 excretion in humans consuming maize-based diets. Mol Nutr Food Res (in press).
57. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, et al. 2009. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 78: 743-768.
58. Sadler TW, Merrill AH, Stevens VL, et al. 2002. Prevention of fumonisin B1-induced neural tube defects by folic acid. Teratology 66: 169-176.
59. Sato K, Malchinkhuu E, Horiuchi Y, et al. 2007. Critical role of ABCA1 transporter in sphingosine 1-phosphate release from astrocytes. J Neurochem 103: 2610-2619.
60. Shephard GS, Marasas WF, Burger HM, et al. 2007. Exposure assessment for fumonisins in the former Transkei region of South Africa. Food Addit Contam 24: 621-629.
61. Shephard GS, Thiel PG, Stockenstrom S, et al. 1996. Worldwide survey of fumonisin contamination of corn and corn-based products. J AOAC Int 79: 671-687.
62. Silva LJ, Pena A, Lino CM, et al. 2010. Fumonisins determination in urine by LC-MS-MS. Anal Bioanal Chem 396: 809-816.
63. Solfrizzo M, Gambacorta L, Lattanzio VM, et al. 2011. Simultaneous LC-MS/MS determination of aflatoxin M1, ochratoxin A, deoxynivalenol, de-epoxydeoxynivalenol, alpha and beta-zearalenols and fumonisin B1 in urine as a multi-biomarker method to assess exposure to mycotoxins. Anal Bioanal Chem 401: 2831-2841.
64. Sonnino S, Chigorno V. 2000. Ganglioside molecular species containing C18- and C20-sphingosine in mammalian nervous tissues and neuronal cell cultures. Biochim Biophys Acta 1469: 63-77.
65. Spiegel S, English D, Milstien S, et al. 2002a. Sphingosine 1-phosphate signaling: providing cells with a sense of direction. Trends Cell Biol 12: 236-242.
66. Spiegel S, Milstien S. 2002b. Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 277: 25851-25854.
67. Spiegel S, Milstien S. 2003a. Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways. Biochem Soc Trans 31: 1216-1219.
68. Spiegel S, Milstien S. 2003b. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4: 397-407.
69. Takabe K, Paugh SW, Milstien S, et al. 2008. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60: 181-195.
70. Teufel A, Maass T, Galle PR, et al. 2009. The longevity assurance homologue of yeast lag1 (Lass) gene family (review). Int J Mol Med 23: 135-140.
71. Torres OA, Palencia E, Lopez de Pratdesaba L, et al. 2007. Estimated fumonisin exposure in Guatemala is greatest in consumers of lowland maize. J Nutr 137: 2723-2729.
72. van der Westhuizen L, Shephard GS, Burger HM, et al. 2011. Fumonisin B1 as a urinary biomarker of exposure in a maize intervention study among South African subsistence farmers. Cancer Epidemiol Biomarkers Prev 20: 483-489.
73. Voss KA, Gelineau-van Waes JB, Riley RT, et al. 2006. Fumonisins: current research trends in developmental toxicology. Mycotoxin Res 22: 61-69.
74. Wall NA, Craig EJ, Labosky PA, et al. 2000. Mesendoderm induction and reversal of left-right pattern by mouse Gdf1, a Vg1-related gene. Dev Biol 227: 495-509.
75. Wang B, Shi G, Fu Y, et al. 2007. Cloning and characterization of a LASS1-GDF1 transcript in rat cerebral cortex: conservation of a bicistronic structure. DNA Seq 18: 92-103.
76. Wang E, Norred WP, Bacon CW, et al. 1991. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. J Biol Chem 266: 14486-14490.
77. Watterson K, Sankala H, Milstien S, et al. 2003. Pleiotropic actions of sphingosine-1-phosphate. Prog Lipid Res 42: 344-357.
78. Weis BK, Balshaw D, Barr JR, et al. 2005. Personalized exposure assessment: promising approaches for human environmental health research. Environ Health Perspect 113: 840-848.
79. Wendler CC, Rivkees SA. 2006. Sphingosine-1-phosphate inhibits cell migration and endothelial to mesenchymal cell transformation during cardiac development. Dev Biol 291: 264-277.
80. Xiao KZ, Zhang ZY, Su YM, et al. 1990. Central nervous system congenital malformations, especially neural tube defects in 29 provinces, metropolitan cities and autonomous regions of China: Chinese Birth Defects Monitoring Program. Int J Epidemiol 19: 978-982.
81. Yamanaka M, Anada Y, Igarashi Y, et al. 2008. A splicing isoform of LPP1, LPP1a, exhibits high phosphatase activity toward FTY720 phosphate. Biochem Biophys Res Commun 375: 675-679.
82. Zhou J, Saba JD. 1998. Identification of the first mammalian sphingosine phosphate lyase gene and its functional expression in yeast. Biochem Biophys Res Commun 242: 502-507.
83. Zitomer NC, Glenn AE, Bacon CW, et al. 2008. A single extraction method for the analysis by liquid chromatography/tandem mass spectrometry of fumonisins and biomarkers of disrupted sphingolipid metabolism in tissues of maize seedlings. Anal Bioanal Chem 391: 2257-2263.
84. Zitomer NC, Mitchell T, Voss KA, et al. 2009. Ceramide synthase inhibition by fumonisin B1 causes accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. J Biol Chem 284: 4786-4795.